A novel UPLC-UV method was developed for analysis of timolol in human plasma using a simple, fast, and cost effective ion-exchange SPE procedure, followed by separation on a C UPLC column with a mobile phase consisting of acetonitrile, phosphate buffer, and sodium 1-octane sulfonate as an ion pairing agent. The method was fully validated according to US-FDA guidelines, and was found to be sufficiently accurate and precise for analysis of timolol in human plasma for clinical pharmacokinetic studies. The application of ion-exchange SPE cartridges for purification of timolol in plasma produced excellent percent recoveries and good sample clean-up, while the ion-pairing separation described here allowed quantitation of timolol without interference from endogenous sample components. The method lower limit of detection was 1.7 ng/mL and the lower limit of quantitation was 5.0 ng/mL, allowing for analysis of therapeutic concentrations of timolol in plasma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchromb.2018.08.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Timolol 0.5% Eye Drops for Essential Tremor: First Successful Case Report.
Mo Med
December 2024
Neurologist specializing in headache treatment, Kansas City, Missouri.
This paper presents a new treatment modality, timolol 0.5% eye drops either topical to normal eyes or preferably by a compounded nasal spray for episodic use in patients with mild to moderate essential tremor. This would primarily be patients wishing to damp their tremors on certain occasions or who were not able to tolerate daily oral beta blockers.
View Article and Find Full Text PDFEfficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%/Timolol 0.5% vs. Dorzolamide 2%/Timolol 0.5% in Indian Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized Phase 3 Study.
Cureus
November 2024
Medical Affairs, Sun Pharma Laboratories Limited, Mumbai, IND.
Introduction Fixed-dose combinations (FDCs) have the potential in glaucoma management to improve efficacy due to the complementary mechanism of action of the drugs as well as compliance while reducing adverse effects by minimizing exposure to preservatives and the financial burden on the patients. FDC of brinzolamide/timolol has demonstrated efficacy and safety in multinational phase 3 studies in primary open-angle glaucoma (POAG) and ocular hypertension. However, efficacy and safety in the Indian population are not known.
View Article and Find Full Text PDFUnlabelled: Safe and effective glaucoma treatment remains a critical task in ophthalmology. Newly introduced medications, in addition to mandatory registration trials, are also evaluated in real-world clinical settings.
Purpose: This study assesses the efficacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in patients with primary open-angle glaucoma (POAG) in real-world clinical settings.
[Approaches for improvement of ocular surface condition in primary open-angle glaucoma].
Vestn Oftalmol
November 2024
Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan.
Purpose: This study compares the effectiveness of various approaches to improvement of ocular surface condition in primary open-angle glaucoma (POAG) patients with dry eye syndrome (DES) and meibomian gland dysfunction (MGD).
Material And Methods: The study included 48 patients with stage II POAG, compensated with a fixed-combinations of dorzolamide and timolol (FC-DT) containing benzalkonium chloride (BAC), in the presence of DES and MGD. After randomization, patients in group 1 (=24) received FC-DT without BAC along with eyelid hygiene ("Blepharogel cleansing", "Blepharolotion", "Blepharogel-1"), while patients in group 2 received only FC-DT without BAC.
β-Blockers and Asthma: Surprising findings from the FAERS database.
Respir Med
November 2024
Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Introduction: β-Blockers are essential for cardiovascular disease management but can induce respiratory issues, particularly with non-selective β-blockers. Their safety in asthmatic patients is debated.
Objective: This study investigates the link between different classes of β-blockers and the risk of asthma and asthma-like adverse events (AEs) using data from the Food and Drug Administration's Adverse Event Reporting System (FAERS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!